Clinical Trials Logo

Clinical Trial Summary

The main question of this study is if and when VEGF (vascular endothelial growth factor) expression in the tumor is upregulated during chemoradiation and if bevacizumab inhibits subsequent vessel growth in the tumor.

- Therefore the first aim of this study is to identify the time point of induction of VEGF in the tumor tissue of esophagus carcinoma during chemoradiation (after 1,2,3 or 4 weeks of chemoradiation).

- If we identify increased expression of VEGF at a certain time point, our second aim is to determine if we can inhibit the subsequent tumor vessel growth by administration of bevacizumab.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02072720
Study type Interventional
Source VU University Medical Center
Contact Henk Verheul, MD/ PhD
Email h.verheul@vumc.nl
Status Recruiting
Phase Early Phase 1
Start date February 2014
Completion date May 1, 2021